Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies.
Recent Financial and Business Updates:
Second Quarter 2023 Results:
- Robust Product Revenue Growth: Product revenue saw a substantial 14% increase, reaching USD 2.49 billion in the second quarter of 2023. This growth was primarily attributed to the strong adoption of TRIKAFTA/KAFTRIO in multiple international markets and continued performance of TRIKAFTA in the U.S., particularly with its recent launch for children aged 2 to 5 with cystic fibrosis (CF).
- Increased Investment in Research and Development (R&D): Vertex witnessed a notable rise in both GAAP and Non-GAAP R&D expenses, which reached USD 1.2 billion and USD 1.0 billion, respectively, compared to USD 877 million and USD 750 million in the second quarter of 2022. This increase was driven by augmented investment in support of various mid- and late-stage clinical programs, acquired IPR&D costs, and expenditures linked to global therapy launches.
- Stable Tax Rates: The GAAP effective tax rate for the second quarter of 2023 stood at 21.2%, slightly higher than the 20.9% recorded in the same period of 2022. Meanwhile, the Non-GAAP effective tax rate in the second quarter of 2023 was 21.0%, down from 21.8% in the corresponding quarter of the previous year.
- Improved Net Income: Both GAAP and Non-GAAP net income displayed positive growth, increasing by 13% and 9%, respectively, compared to the second quarter of 2022. This growth was mainly attributed to robust revenue expansion and increased interest income, partially offset by elevated investments in the mid- and late-stage clinical pipeline, acquired IPR&D expenses, and global therapy launch costs.
- Strengthened Financial Position: As of June 30, 2023, Vertex's cash, cash equivalents, and marketable securities amounted to USD 12.6 billion, an increase from USD 10.9 billion as of December 31, 2022. This increase primarily resulted from strong revenue growth and operating cash flow, partially offset by payments to collaborators, share repurchases, and income tax payments.
- Full Year 2023 Financial Guidance: Vertex has revised its full-year 2023 CF product revenue guidance upwards to USD 9.7 to USD 9.8 billion, reflecting the anticipated impact of TRIKAFTA/KAFTRIO's global adoption and continued TRIKAFTA performance. The guidance accounts for foreign currency rate fluctuations and higher acquired IPR&D expenses, demonstrating Vertex's optimistic outlook.
- Key Business Highlights: Vertex expects continued growth in the number of CF patients benefiting from its medicines, including younger patients. Recent milestones include approvals for pediatric usage, real-world studies showcasing treatment benefits, and regulatory submissions for expanded age groups.
Technical Observation (on the daily chart)
The stock has given a return of 27.38% from its 52-week low, which was formed on September 26, 2022. The Relative Strength Index (RSI) over a 14-day period stands at 56.22, heading upwards, with expectations of some consolidation before a continuation of the uptrend. Meanwhile, the stock price is above both the 21-day Simple Moving Average (SMA) and the 50-day SMA, therefore these SMAs can act as short-term support in case the price corrects.
As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a “WATCH” rating is recommended for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) at its current price of USD353.98 as on September 22, 2023, at 8:15 am PDT.
Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
How to Read the Charts?
The yellow colour line reflects the 21-period simple moving average (SMA) while the blue line indicates the 50- period simple moving average (SMA). SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.
The orange colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.
The red and green colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps with easier and faster execution of the order.
The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.
Technical Indicators Defined: -
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
The reference date for all price data, currency, technical indicators, support, and resistance levels is September 22, 2023. The reference data in this report has been partly sourced from REFINITIV.
Abbreviations
CMP: Current Market Price
SMA: Simple Moving Average
RSI: Relative Strength Index
USD: United States dollar
Note: Trading decisions require a thorough analysis by individual. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating the stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.